Abstract
Potential DMRs were selected based on receiver operating characteristic (ROC) analysis performed using the methylation level (mean β value of probes within each window). [...]the β values of the 25 DMRs were analyzed in 440 BCa, 21 BCa-NAT, 324 kidney renal clear cell carcinoma (KIRC), 275 kidney renal papillary cell carcinoma (KIRP) samples from The Cancer Genome Atlas (TCGA) database, and 656 healthy blood samples from the Gene Expression Omnibus (GEO) database. After considering the background noise in healthy blood/NATs and the feasibility of primer design, eight DMRs were selected for further testing in 30 healthy blood samples and 20 normal urine samples using polymerase chain reaction (PCR) and Sanger sequencing. Furthermore, a positive detection of this molecular urine test, followed by more sensitive narrow-band imaging or photodynamic diagnosis, could decrease false-negative rates when compared with white light cystoscopy. [...]this simple and efficient diagnostic test has great clinical application prospects.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Urology, Peking University First Hospital, Beijing 100034, China; Institute of Urology, Peking University, Beijing 100034, China; National Urological Cancer Center, Beijing 100034, China; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China
2 Wuhan Ammunition Life-tech Company, Ltd., Wuhan, Hubei 430200, China